Linker Information
General Information of This Linker
| Linker ID |
LIN0YIZVG
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Mc-Gly-Gly-Phe-Gly-AM
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C26H34N6O7
|
|||||
| Isosmiles |
CNC(=O)CNC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)CCCCCN1C(=O)C=CC1=O
|
|||||
| InChI |
InChI=1S/C26H34N6O7/c1-27-21(34)15-30-26(39)19(14-18-8-4-2-5-9-18)31-23(36)17-29-22(35)16-28-20(33)10-6-3-7-13-32-24(37)11-12-25(32)38/h2,4-5,8-9,11-12,19H,3,6-7,10,13-17H2,1H3,(H,27,34)(H,28,33)(H,29,35)(H,30,39)(H,31,36)
|
|||||
| InChIKey |
LETKGXXMROUGGW-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
542.593
|
Polar area
|
182.88
|
||
|
Complexity
|
39
|
xlogp Value
|
-1.7061
|
|||
|
Heavy Count
|
39
|
Rot Bonds
|
16
|
|||
|
Hbond acc
|
7
|
Hbond Donor
|
5
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
ZW191 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligibility: Locally advanced/unresectable or metastatic cancer (measurable per RECIST v1.1), ECOG 0-1, LVEF ≥50%, and adequate organ function. Exclusions: active malignancies requiring treatment, prior TOPO1i ADC therapy, uncontrolled organ dysfunction (renal/liver/pancreatic), or severe active infections (including SARS-CoV-2) needing systemic therapy.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06555744 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors
|
||||
| Primary Endpoint |
Primary safety outcomes (Parts 1-2) include dose-limiting toxicities (DLTs) evaluated within 3 weeks, treatment-related adverse events (AEs), special interest AEs (AESIs), serious AEs (SAEs), and Grade 3+ lab abnormalities per CTCAE v5.0. Key efficacy measures (Part 2) focus on confirmed objective response rate (ORR) by RECIST v1.1 (CR/PR).
|
||||
| Other Endpoint |
Secondary endpoints (Parts 1-2) assess clinical benefit rate (CR/PR/non-CR non-PD/SD lasting ≥180 days), duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), and best overall response (BOR). Pharmacokinetics (serum concentrations & ADA development) will be monitored throughout the study.
|
||||